293 related articles for article (PubMed ID: 33066112)
1. Advances, Perspectives and Potential Engineering Strategies of Light-Gated Phosphodiesterases for Optogenetic Applications.
Tian Y; Yang S; Gao S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066112
[TBL] [Abstract][Full Text] [Related]
2. Revisiting and Redesigning Light-Activated Cyclic-Mononucleotide Phosphodiesterases.
Stabel R; Stüven B; Hansen JN; Körschen HG; Wachten D; Möglich A
J Mol Biol; 2019 Aug; 431(17):3029-3045. PubMed ID: 31301407
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
Brescia M; Zaccolo M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
[TBL] [Abstract][Full Text] [Related]
4. The perspective of cAMP/cGMP signaling and cyclic nucleotide phosphodiesterases in aortic aneurysm and dissection.
Shu T; Zhou Y; Yan C
Vascul Pharmacol; 2024 Mar; 154():107278. PubMed ID: 38262506
[TBL] [Abstract][Full Text] [Related]
5. Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry.
Reinecke D; Schwede F; Genieser HG; Seifert R
PLoS One; 2013; 8(1):e54158. PubMed ID: 23342095
[TBL] [Abstract][Full Text] [Related]
6. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
Keravis T; Lugnier C
Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
[TBL] [Abstract][Full Text] [Related]
7. Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.
Zhao CY; Greenstein JL; Winslow RL
J Mol Cell Cardiol; 2016 Feb; 91():215-27. PubMed ID: 26773602
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
Zhang L; Bouadjel K; Manoury B; Vandecasteele G; Fischmeister R; Leblais V
Br J Pharmacol; 2019 Jun; 176(11):1780-1792. PubMed ID: 30825186
[TBL] [Abstract][Full Text] [Related]
9. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system.
Maurice DH
Front Biosci; 2005 May; 10():1221-8. PubMed ID: 15769620
[TBL] [Abstract][Full Text] [Related]
10. Optogenetic tools for manipulation of cyclic nucleotides functionally coupled to cyclic nucleotide-gated channels.
Henß T; Nagpal J; Gao S; Scheib U; Pieragnolo A; Hirschhäuser A; Schneider-Warme F; Hegemann P; Nagel G; Gottschalk A
Br J Pharmacol; 2022 Jun; 179(11):2519-2537. PubMed ID: 33733470
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters.
Cheepala S; Hulot JS; Morgan JA; Sassi Y; Zhang W; Naren AP; Schuetz JD
Annu Rev Pharmacol Toxicol; 2013; 53():231-53. PubMed ID: 23072381
[TBL] [Abstract][Full Text] [Related]
12. Elucidating cyclic AMP signaling in subcellular domains with optogenetic tools and fluorescent biosensors.
Klausen C; Kaiser F; Stüven B; Hansen JN; Wachten D
Biochem Soc Trans; 2019 Dec; 47(6):1733-1747. PubMed ID: 31724693
[TBL] [Abstract][Full Text] [Related]
13. Molecular Properties and Optogenetic Applications of Enzymerhodopsins.
Tsunoda SP; Sugiura M; Kandori H
Adv Exp Med Biol; 2021; 1293():153-165. PubMed ID: 33398812
[TBL] [Abstract][Full Text] [Related]
14. Enzyme assays for cGMP hydrolyzing phosphodiesterases.
Rybalkin SD; Hinds TR; Beavo JA
Methods Mol Biol; 2013; 1020():51-62. PubMed ID: 23709025
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular genetics of the phosphodiesterases (PDEs).
Azevedo MF; Faucz FR; Bimpaki E; Horvath A; Levy I; de Alexandre RB; Ahmad F; Manganiello V; Stratakis CA
Endocr Rev; 2014 Apr; 35(2):195-233. PubMed ID: 24311737
[TBL] [Abstract][Full Text] [Related]
16. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
Kokkonen K; Kass DA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
Preedy MEJ
Cardiovasc Drugs Ther; 2020 Jun; 34(3):401-417. PubMed ID: 32172427
[TBL] [Abstract][Full Text] [Related]
18. In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors.
Rich TC; Tse TE; Rohan JG; Schaack J; Karpen JW
J Gen Physiol; 2001 Jul; 118(1):63-78. PubMed ID: 11429444
[TBL] [Abstract][Full Text] [Related]
19. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.
Mehats C; Andersen CB; Filopanti M; Jin SL; Conti M
Trends Endocrinol Metab; 2002; 13(1):29-35. PubMed ID: 11750860
[TBL] [Abstract][Full Text] [Related]
20. Protein-Protein Interactions of Phosphodiesterases.
Al-Nema MY; Gaurav A
Curr Top Med Chem; 2019; 19(7):555-564. PubMed ID: 30931862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
